Advertisement

Sirolimus-Coated Balloon: Insights on a New Technology for Coronary Use

  • Gaetano Di Palma
  • Bernardo Cortese
Chapter

Abstract

Nowadays, limus-eluting stents dominate the world of drug-eluting stents (DES) and proved to be superior to paclitaxel-eluting stents in terms of efficacy and safety [1].

References

  1. 1.
    Windecker S, Stortecky S, Stefanini GG, da Costa BR, Rutjes AW, Di Nisio M, Silletta MG, Maione A, Alfonso F, Clemmensen PM, Collet J-P, Cremer J, Falk V, Filippatos G, Hamm C, Head S, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann F-J, Richter D, Schauerte P, Sousa Uva M, Taggart DP, Torracca L, Valgimigli M, et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ. 2014;348:g3859.CrossRefGoogle Scholar
  2. 2.
    Wöhrle J. Drug-coated balloons for coronary and peripheral interventional procedures. Curr Cardiol Rep. 2012;14:635–41.CrossRefGoogle Scholar
  3. 3.
    Scheller B, Speck U, Abramjuk C, Bernhardt U, Böhm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004;110:810–4.CrossRefGoogle Scholar
  4. 4.
    Cortese B, Bertoletti A. Paclitaxel coated balloons for coronary artery interventions: a comprehensive review of preclinical and clinical data. Int J Cardiol. 2012;161:4–12.CrossRefGoogle Scholar
  5. 5.
    Kaule S, Minrath I, Stein F, Kragl U, Schmidt W, Schmitz K-P, Sternberg K, Petersen S. Correlating coating characteristics with the performance of drug-coated balloons – a comparative in vitro investigation of own established hydrogel- and ionic liquid-based coating matrices. PLoS One. 2015;10:e0116080.CrossRefGoogle Scholar
  6. 6.
    Windecker S, Kolh P, Alfonso F, Collet J-P, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann F-J, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS guidelines on myocardial revascularization. EuroIntervention. 2015;10:1024–94.CrossRefGoogle Scholar
  7. 7.
    Wöhrle J, Zadura M, Möbius-Winkler S, Leschke M, Opitz C, Ahmed W, Barragan P, Simon J-P, Cassel G, Scheller B. SeQuent Please World Wide Registry: clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study. J Am Coll Cardiol. 2012;60:1733–8.CrossRefGoogle Scholar
  8. 8.
    Lemos PA, Farooq V, Takimura CK, Gutierrez PS, Virmani R, Kolodgie F, Christians U, Kharlamov A, Doshi M, Sojitra P, van Beusekom HMM, Serruys PW. Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. EuroIntervention. 2013;9:148–56.CrossRefGoogle Scholar
  9. 9.
    Parikh KH, Shetty R, Dani S, Bhatt P, Doshi M, Sojitra P. Real-world safety and outcome measures of novel sirolimus coated balloon catheter. J Am Coll Cardiol. 2016;67:225.CrossRefGoogle Scholar
  10. 10.
    Clever YP, Peters D, Calisse J, Bettink S, Berg M-C, Sperling C, Stoever M, Cremers B, Kelsch B, Böhm M, Speck U, Scheller B. Novel sirolimus-coated balloon catheter: in vivo evaluation in a porcine coronary model. Circ Cardiovasc Interv. 2016;e003543:9.Google Scholar
  11. 11.
    Verheye S, Vrolix M, Kumsars I, Erglis A, Sondore D, Agostoni P, Cornelis K, Janssens L, Maeng M, Slagboom T, Amoroso G, Jensen LO, Granada JF, Stella P. The SABRE trial (sirolimus angioplasty balloon for coronary in-stent restenosis): angiographic results and 1-year clinical outcomes. JACC Cardiovasc Interv. 2017;10:2029–37.CrossRefGoogle Scholar
  12. 12.
    Cortese B, Dani S, Parikh K, Kumar P. TCT-643 safety and efficacy of Sirolimus coated balloon for the treatment of coronary lesions in small vessels: a subgroup analysis from the Nanolute registry. J Am Coll Cardiol. 2017;70:B283.CrossRefGoogle Scholar
  13. 13.
    Dani S, Parikh K, Kumar P. TCT-210 Sirolimus coated balloon in the treatment of coronary artery disease in diabetic patients: results from Nanolute registry. J Am Coll Cardiol. 2017;70:B88–9.CrossRefGoogle Scholar
  14. 14.
    Parikh K, Dani S, Kumar P. TCT-641 Sirolimus coated balloon for the treatment of coronary in-stent restenosis: insights from Nanolute registry. J Am Coll Cardiol. 2017;70:B283.CrossRefGoogle Scholar
  15. 15.
    Waksman R, Serra A, Loh JP, Malik FT-N, Torguson R, Stahnke S, Strandmann von RP, Rodriguez AE. Drug-coated balloons for de novo coronary lesions: results from the Valentines II trial. EuroIntervention. 2013;9:613–9.CrossRefGoogle Scholar
  16. 16.
    Cortese B, Di Palma G, Latini RA, Elwany M, Orrego PS, Seregni RG. Immediate and short-term performance of a novel sirolimus-coated balloon during complex percutaneous coronary interventions. The FAtebenefratelli SIrolimus COated-balloon (FASICO) registry. Cardiovasc Revasc Med. 2017;18(7):487–91.CrossRefGoogle Scholar
  17. 17.
    Cortese B, Sgueglia GA, Berti S, Biondi-Zoccai G, Colombo A, Limbruno U, Bedogni F, Cremonesi A, Italian Society of Interventional Cardiology (SICI-GISE). SICI-GISE position paper on drug-coated balloon use in the coronary district. G Ital Cardiol. 2013;14(10):681–9.Google Scholar
  18. 18.
    Cortese B, Berti S, Biondi-Zoccai G, Colombo A, Limbruno U, Bedogni F, Cremonesi A, Silva PL, Sgueglia GA, Italian Society of Interventional Cardiology. Drug-coated balloon treatment of coronary artery disease: a position paper of the Italian Society of Interventional Cardiology. Catheter Cardiovasc Interv. 2014;83(3):427–35.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Gaetano Di Palma
    • 1
  • Bernardo Cortese
    • 1
  1. 1.Cardiac DepartmentSan Carlo ClinicMilanoItaly

Personalised recommendations